Regimen for the treatment of hair loss disorders with deuterated JAK inhibitors

JP2023553253A5Inactive Publication Date: 2024-11-01SUN PHARMACEUTICAL IND INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526173
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-03-02
Filing Date
2021-10-28
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is no known cure for alopecia areata, a significant autoimmune disease causing partial or complete hair loss that affects millions and has severe psychological consequences, necessitating improved treatments.

Method used

The use of a deuterated analogue of ruxolitinib, known as CTP-543, administered in specific dosage regimens over defined periods to treat hair loss disorders, including alopecia areata, by modulating Janus Associated Kinases JAK1 and JAK2 activity.

Benefits of technology

CTP-543 demonstrates significant hair regrowth as measured by reduced SALT scores, with up to 90% improvement in hair loss after 24 weeks, maintaining hair growth with lower doses in a second period, and is well-tolerated with minimal adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed is a method for treating a hair loss disorder in a subject, which is beneficially treated by administering a JAK1 and / or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof. [Formula 1] TIFF2023553253000020.tif38115
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Cross-reference to Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 61 / 106,790, filed Oct. 28, 2020, and U.S. Provisional Patent Application No. 63 / 155,637, filed Mar. 2, 2021. The entire teachings of the above applications are incorporated herein by reference.

[0002] Alopecia areata (AA) is an autoimmune disease that results in partial or complete loss of hair on the scalp and body. The scalp is the most commonly affected area, but any hairy area can be affected alone or in conjunction with the scalp. In the United States, at any given time, up to 650,000 patients, including men, women, and children, are affected by alopecia areata (AA). AA has a significant impact on patients, and AA is associated with severe psychological consequences such as anxiety and depression, and other autoimmune conditions.

[0003] There is no known cure for AA. Improved treatments for AA and other hair loss disorders are needed.

Summary of the Invention

[0004] It has been found that a deuterated analog of ruxolitinib ((R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyclopentyl-2,2,3,3,4,4,5,5-d8)propanenitrile, or D8-ruxolitinib, or CTP-543, also referred to as compound (I)) is useful in the treatment of hair loss disorders including alopecia areata. The published PCT application WO17 / 192905 describes the use of CTP-543 for the treatment of alopecia areata. Compound (I) is represented by the following structural formula.

Chemical

[0005] In certain embodiments, compound (I) is administered as a pharmaceutically acceptable salt, such as a phosphate. Compound (I) can be administered as a single daily dose or in divided doses (e.g., twice daily) in a dose ranging from about 8 mg to about 32 mg per day (or an equivalent weight based on a salt such as compound (I) phosphate). Based on these findings, novel therapies using compound (I) or a pharmaceutically acceptable salt thereof for the treatment of alopecia disorders in mammalian subjects are disclosed herein.

[0006] In one embodiment, the present invention provides a method for treating alopecia disorders in human subjects, the method comprising administering a compound represented by the following structural formula to the subject: [ka] Each position explicitly designated as deuterium has at least 95% deuterium incorporation, or a pharmaceutically acceptable salt thereof. Compound (I) The compound or a pharmaceutically acceptable salt thereof is administered (1) in an amount ranging from approximately 8 mg to approximately 32 mg per day for a first period of 8 to 24 weeks, followed by (2) a second period of at least 8 weeks, in which the compound or a pharmaceutically acceptable salt thereof is administered at 50 to 75% of the amount administered in the first period, to treat the alopecia disorder.

[0007] In certain embodiments, the hair loss disorder is alopecia areata.

[0008] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 12 mg / day, about 16 mg / day, about 24 mg / day, or about 32 mg / day.

[0009] In certain embodiments, during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 6 mg / day, approximately 8 mg / day, approximately 12 mg / day, or approximately 16 mg / day.

[0010] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 24 mg / day, and during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 16 mg / day. In certain embodiments, approximately 24 mg / day of the compound or salt is administered once daily, and approximately 16 mg / day of the compound or salt is administered once daily. In certain embodiments, approximately 24 mg / day of the compound or salt is administered twice daily at approximately 12 mg / day, and approximately 16 mg / day of the compound or salt is administered twice daily at approximately 8 mg.

[0011] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 16 mg / day, and during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 8 mg / day. In certain embodiments, approximately 16 mg / day of the compound or salt is administered once daily, and approximately 8 mg / day of the compound or salt is administered once daily. In certain embodiments, approximately 16 mg / day of the compound or salt is administered twice daily at approximately 8 mg / day, and approximately 8 mg / day of the compound or salt is administered twice daily at approximately 4 mg.

[0012] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered orally.

[0013] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical formulation, which is a tablet.

[0014] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered once daily during the first period. In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered twice daily during the first period.

[0015] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered once daily during the second period. In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered twice daily during the second period.

[0016] In certain embodiments, the first period is approximately 8 to 24 weeks. In certain embodiments, the first period is approximately 12 weeks. In certain embodiments, the first period is approximately 16 weeks. In certain embodiments, the first period is approximately 20 weeks. In certain embodiments, the first period is approximately 24 weeks. In certain embodiments, the second period is at least 12 weeks. In certain embodiments, the second period is at least 24 weeks.

[0017] In certain embodiments, the first period is approximately 8 to 12 weeks. In certain embodiments, the first period is approximately 8 weeks. In certain embodiments, the first period is approximately 12 weeks. In certain embodiments, the first period is at least 8 weeks.

[0018] In certain embodiments, in compound (I), each position explicitly designated as deuterium has at least 97% deuterium incorporation.

[0019] Another aspect of the present invention is compound (I) or a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as a phosphate) for use in the treatment of alopecia disorders, which can be treated with compounds that modulate the activity of Janus Associated Kinase 1 (JAK1) and / or Janus Associated Kinase 2 (JAK2). The compound may be administered in the dosing regimens disclosed herein. In a particular embodiment, the alopecia disorder is alopecia areata.

[0020] A further aspect of the present invention is the use of compound (I) or a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as a phosphate) to produce a pharmaceutical for treating a hair loss disorder that can be treated by a compound that modulates the activity of Janus Associated Kinase 1 (JAK1) and / or Janus Associated Kinase 2 (JAK2). The compound may be administered in the dosing regimens disclosed herein. In a particular embodiment, the hair loss disorder is alopecia areata. [Brief explanation of the drawing]

[0021] [Figure 1] Figure 1 shows the proportion of responders at week 24 of the Phase 2a trial (patients with a SALT score reduction of 50% or more compared to baseline), and this cohort includes placebo, 4 mg BID, 8 mg BID, and 12 mg BID cohorts. [Figure 2] Figure 2 shows the proportion of responders by hospital visit in the Phase 2a trial (patients with a SALT score reduction of 50% or more compared to baseline), and this cohort includes placebo, 4 mg BID, 8 mg BID, and 12 mg BID cohorts. [Figure 3] Figure 3 shows the proportion of responders by hospital visit in the Phase 2a trial (patients with a SALT score reduction of 75% or more compared to baseline), and this cohort includes placebo, 4 mg BID, 8 mg BID, and 12 mg BID cohorts. [Figure 4] Figure 4 shows the proportion of responders by hospital visit in the Phase 2a trial (patients with a SALT score reduction of 90% or more compared to baseline), and this cohort includes placebo, 4 mg BID, 8 mg BID, and 12 mg BID cohorts. [Figure 5] Figure 5 shows the improvement of the SALT score of patients after 24 weeks of the Phase 2a trial, and this cohort includes placebo, 4 mg BID, 8 mg BID, and 12 mg BID cohorts. [Figure 6] Figure 6 shows the relative change in the SALT score by hospital visit in the Phase 2a trial, and this cohort includes placebo, 4 mg BID, 8 mg BID, and 12 mg BID cohorts. [Figure 7] Figure 7 shows the design of a study for administering compound (I) (CTP-543) at 8 mg BID or 12 mg BID for a first period, and then administering a lower dose of compound (I) or placebo for a second period. [Figure 8]Figure 8 shows the entry and disposition of subjects in the open-label extension (OLE) trial of compound (I) (CTP-543).

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] definition The term "treating" means reducing, suppressing, attenuating, decreasing, arresting, or stabilizing the onset or progression of a disease (e.g., a disease or disorder detailed herein), reducing the severity of a disease, or ameliorating a symptom associated with a disease. For example, treating a hair loss disorder includes hair regrowth, preventing further hair loss, or decreasing the rate of hair loss.

[0023] "Hair loss disorder" means any condition or disorder that results in the loss of hair in one or more areas of the body. Hair loss disorders include, but are not limited to, androgenetic alopecia, alopecia areata, telogen effluvium, alopecia areata, alopecia totalis, and alopecia universalis.

[0024] The effectiveness of treatments for alopecia areata and other hair loss disorders can be measured in various ways, some of which are known in the art. For example, the “severity of alopecia tool,” known as SALT, is a validated assessment scale developed by the working committee of the National Alopecia Areata Foundation to evaluate the degree of hair loss. See, for example, Olsen EA, Hordinsky MK, Price VH et al. Guidelines for the Evaluation of Alopecia Areata Clinical Trials - Part II. J Am Acad Dermatol 2004:51:440-447 (incorporated herein by reference). The SALT score is calculated for a patient by measuring the percentage of hair loss in each of the four areas of the scalp and adding them up to reach an aggregate value. Hair regrowth is reflected by a decrease in the SALT score. For example, no hair on the scalp has a SALT score of 100, while complete hair regrowth has a SALT score of 0. In certain embodiments, the treatment method described herein can provide an improvement of at least 10 points in the SALT score after treatment (for example, from a SALT score of 100 before treatment to a SALT score of 90 after treatment). In further embodiments, the treatment method described herein can result in an improvement of at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 points in the SALT score. In certain embodiments, the treatment method described herein can provide an improvement of at least 20% from the baseline of the patient's SALT score after treatment, or at least 30% from the baseline of the patient's SALT score, or at least 40% from the baseline of the patient's SALT score, or at least 50% from the baseline of the patient's SALT score, or at least 60% from the baseline of the patient's SALT score, or at least 70% from the baseline of the patient's SALT score, or at least 75% from the baseline of the patient's SALT score, or at least 80% from the baseline of the patient's SALT score, or at least 90% from the baseline of the patient's SALT score.

[0025] As used herein, the term “Subject” includes humans, as well as non-human mammals such as cats, dogs, sheep, cattle, pigs, goats, and non-human primates (including monkeys and hominins).

[0026] As used herein, the term “about” means “approximately,” that is, within an acceptable margin of error for a given value as determined by those skilled in the art. For example, “about” could mean a range of up to 10% above or below a given value, a range of up to 5% above or below a given value, or a range of up to 1% above or below a given value. Furthermore, if the given value is a length of time of several weeks, the term “about” could mean up to approximately two weeks, or up to approximately one week.

[0027] It is recognized that, depending on the origin of the chemicals used in synthesis, some variation in the natural isotopic abundances occurs in the synthesized compound. Therefore, ruxolitinib preparations essentially contain small amounts of deuterated isotopic substitutions. The concentrations of naturally abundant and stable hydrogen and carbon isotopes are small and non-material compared to the degree of stable isotopic substitution in the compounds of the present invention, despite this variation. See, for example, Wada, E et al., Seikagaku, 1994, 66:15; Gannes, LZ et al., Comp Biochem Physiol Mol Integr Physiol, 1998, 119:725.

[0028] In compound (I), any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, where a position is explicitly designated as "H" or "hydrogen," that position is understood to have hydrogen in its naturally occurring isotopic composition. However, in the specific embodiments described, when a position is explicitly designated as "H" or "hydrogen," that position has at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% hydrogen. In some embodiments, as described in detail, when a position is explicitly designated as "H" or "hydrogen," that position incorporates ≤20% deuterium, ≤10% deuterium, ≤5% deuterium, ≤4% deuterium, ≤3% deuterium, ≤2% deuterium, or ≤1% deuterium. Furthermore, unless otherwise specified, if a position is clearly designated as "D" or "deuterium," it is understood that the position contains deuterium at a magnitude of at least 3340 times the natural abundance of deuterium, i.e., 0.015% (i.e., at least 50.1% deuterium incorporation). The amount of deuterium incorporation at the designated position may be measured by analytical methods known to those skilled in the art, for example, by proton NMR.

[0029] As used herein, the term "isotope enrichment factor" means the ratio between the isotopic abundance and the naturally occurring abundance of a given isotope.

[0030] In other embodiments, compound (I) has an isotopic enrichment factor for each designated deuterium position (or atom) of at least 3500 (52.5% deuterium incorporated at each designated deuterium position), at least 4000 (60% deuterium incorporated), at least 4500 (67.5% deuterium incorporated), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporated), at least 6000 (90% deuterium incorporated), at least 6333.3 (95% deuterium incorporated), at least 6466.7 (97% deuterium incorporated), at least 6600 (99% deuterium incorporated), or at least 6633.3 (99.5% deuterium incorporated).

[0031] In some embodiments, each designated deuterium position (or atom) in the compound of the present invention has at least 52.5% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 60% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 67.5% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 75% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 80% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 85% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 90% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 95% deuterium incorporation. In some embodiments, each designated deuterium position in the compound of the present invention has at least 97% deuterium incorporation. In some embodiments, in the compounds of the present invention, each designated deuterium position has at least 98% deuterium incorporation. In some embodiments, in the compounds of the present invention, each designated deuterium position has at least 99% deuterium incorporation. In some embodiments, in the compounds of the present invention, each designated deuterium position has at least 99.5% deuterium incorporation.

[0032] The term "isotope substitution" refers to a molecule whose chemical structure differs from that of compound (I) only in its isotopic composition.

[0033] In the present invention, the term "compound" refers to a group of molecules having the same chemical structure, except that isotopic changes may occur among the constituent molecules of the molecule. Therefore, while compound (I) is represented by a specific chemical structure having deuterium atoms at eight designated positions, it will be apparent to those skilled in the art that compound (I) may contain molecules having deuterium at each of the eight designated positions, and may also contain isotopic substitutions having hydrogen atoms at one or more designated deuterium positions in its structure. The relative amount of such isotopic substitutions in compound (I) depends on several factors, including the isotopic purity of the deuterating reagent used to prepare the compound, and the efficiency of deuterium incorporation in the various synthetic steps used to prepare the compound. In certain embodiments, the relative amount of such isotopic substitutions as a whole is less than 49.9% of the compound. In other embodiments, the relative amount of such isotopic substitutions overall is less than 47.5%, less than 40%, less than 32.5%, less than 25%, less than 17.5%, less than 10%, less than 5%, less than 3%, less than 1%, or less than 0.5% of the compound.

[0034] The present invention also provides salts of compound (I). Salts of the compounds of the present invention are formed between an acidic group and a basic group of a compound, such as an amino acid functional group, or between a base and an acidic group of a compound, such as a carboxyl functional group. According to another embodiment, the compound is a pharmaceutically acceptable acid addition salt, such as a phosphate.

[0035] As used herein, the term “pharmaceutically acceptable” means, within the bounds of sound medical judgment, a component that is suitable for use in contact with human and other mammalian tissues without excessive toxicity, irritation, allergic reactions, etc., and that has a reasonable benefit / risk ratio. “pharmaceutically acceptable salt” means any non-toxic salt that can directly or indirectly provide the compound of the present invention to the recipient upon administration. “pharmaceutically acceptable counterion” is the ionic portion of the salt that is non-toxic when released from the salt upon administration to the recipient.

[0036] Acids commonly used to form pharmaceutically acceptable salts include inorganic acids such as hydrogen disulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, and phosphoric acid, as well as organic acids such as p-toluenesulfonic acid, salicylic acid, tartaric acid, vitalic acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid, as well as related inorganic and organic acids. Therefore, such pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionic acid, decanoic acid, caprylic acid, acrylic acid, formic acid, isobutyric acid, capric acid, heptanoic acid, propiolic acid, oxalates, malonic acid, succinates, suberic acid, sebacates, fumaric acid, maleates, butin-1,4-dioate, and hexin-1,6-dioate. This includes benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, terephthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionic acids, phenylbutyrates, citrates, lactic acid, β-hydroxybutyrate, glycolic acid, maleates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, mandelic acid, and other salts. In one embodiment, pharmaceutically acceptable acid addition salts include those formed from mineral acids such as hydrochloric acid and hydrobromic acid, and in particular those formed from organic acids such as maleic acid.

[0037] As used herein, the term “stable compound” means a compound that is stable enough to enable its manufacture and maintains its integrity for a sufficient period of time to be useful for the purposes detailed herein (e.g., formulation into therapeutic products, intermediates for use in the manufacture of therapeutic compounds, isolateable or storable intermediate compounds, treatment of diseases or conditions that respond to therapeutic agents).

[0038] Both "D" and "d" refer to deuterium. "Stereoisomer" refers to both enantiomers and diastereomers. "Tert" and "t-" refer to tertiary elements, respectively. "US" stands for United States of America.

[0039] "To be substituted with deuterium" means that one or more hydrogen atoms are replaced with a corresponding number of deuterium atoms.

[0040] It has been found that administration of an equivalent amount of compound (I) or a pharmaceutically acceptable salt thereof can result in hair growth after a first period of administration. According to the present invention, the amount of compound (I) or a salt thereof administered to a patient or subject can be reduced during a second treatment period, while maintaining and / or extending (increasing) the hair growth achieved during the first period. Generally, the amount of compound (I) or a salt thereof administered during the second period is sufficient to maintain the hair growth achieved during the first period (e.g., measured by the severity of alopecia tool (SALT) score), and is, for example, about 50-75% of the daily amount administered during the first period (e.g., if 16 mg / day of compound (I) or a salt thereof is administered during the first period, then 8-12 mg / day may be administered during the second period). In certain embodiments, the maintenance dose (the daily amount administered during the second period) is about 33.3% of the daily amount administered during the first period.

[0041] In one embodiment, the present invention provides a method for treating alopecia disorders in human subjects, the method comprising administering a compound represented by the following structural formula to the subject: [ka] The treatment involves administering the compound or a pharmaceutically acceptable salt thereof to a target, where each position expressly designated as deuterium has at least 90% deuterium incorporation, and the compound or a pharmaceutically acceptable salt thereof is administered (1) for a first period, during which the compound or a pharmaceutically acceptable salt thereof is administered in amounts ranging from 8 mg to 32 mg per day, followed by (2) for a second period, during which the compound or a pharmaceutically acceptable salt thereof is administered in amounts that are 50 to 75% of the daily amount administered during the first period, to treat the alopecia disorder. In certain embodiments, the first period is approximately 8 to 24 weeks, e.g., 8 weeks, 12 weeks, 16 weeks, 20 weeks, or 24 weeks. In certain embodiments, the second period is at least 8 weeks, e.g., 8 weeks, 12 weeks, 16 weeks, 20 weeks, or 24 weeks (or longer). Compound (I),

[0042] In one embodiment, the present invention provides a method for treating alopecia disorders in human subjects, the method comprising administering a compound represented by the following structural formula to the subject: [ka] or administering a pharmaceutically acceptable salt thereof to a subject, wherein each position explicitly designated as deuterium has at least 95% deuterium incorporation. The compound or a pharmaceutically acceptable salt thereof is administered (1) for a first period, during which the compound or a pharmaceutically acceptable salt thereof is administered in an amount ranging from 8 mg to 32 mg per day, followed by (2) for a second period, during which the compound or a pharmaceutically acceptable salt thereof is administered in a daily amount that is 50 to 75% of the daily amount administered during the first period, to treat the alopecia disorder. In certain embodiments, the first period is approximately 8 to 24 weeks, for example, 8 weeks, 12 weeks, 16 weeks, 20 weeks, or 24 weeks. In certain embodiments, the second period is at least 8 weeks, for example, 8 weeks, 12 weeks, 16 weeks, 20 weeks, or 24 weeks (or longer).

[0043] In certain embodiments, alopecia is treated if there is a change of 50% or more in the subject's SALT score at the end of the first period compared to the subject's baseline SALT score before treatment. In certain embodiments, alopecia is treated if the subject's SALT score is 20 or less at the end of the second period. In certain embodiments, alopecia is treated if there is a change of 50% or more in the subject's SALT score at the end of the first period compared to the subject's baseline SALT score before treatment, and the subject's SALT score is 20 or less at the end of the second period.

[0044] In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 50 or less, 40 or less, 30 or less, 20 or less, 15 or less, 10 or less, 5 or less, 1 or less, or zero at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 20 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 15 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 10 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 5 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 1 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of zero at the end of the first period.

[0045] In certain embodiments, the hair loss disorder is alopecia areata.

[0046] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 8 mg / day, about 12 mg / day, about 16 mg / day, about 24 mg / day, or about 32 mg / day.

[0047] In certain embodiments, during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 6 mg / day, approximately 8 mg / day, approximately 12 mg / day, approximately 16 mg / day, approximately 18 mg / day, approximately 20 mg / day, or approximately 24 mg / day. In certain embodiments, the maintenance dose (the amount administered per day during the second period) is approximately 33.3% of the amount administered per day during the first period. In certain embodiments, the maintenance dose is approximately 50% of the amount administered per day during the first period. In certain embodiments, the maintenance dose is approximately 66.7% of the amount administered per day during the first period. In certain embodiments, the maintenance dose is approximately 75% of the amount administered per day during the first period.

[0048] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 24 mg / day, and during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 16 mg / day. In certain embodiments, about 24 mg / day is administered as a single dose (i.e., once daily), and about 16 mg / day is administered as a single dose (i.e., once daily). In certain embodiments, about 24 mg / day is administered as two doses of about 12 mg each (i.e., about 12 mg twice daily), and about 16 mg / day is administered as two doses of about 8 mg each (i.e., about 8 mg twice daily).

[0049] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 16 mg / day, and during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 8 mg / day. In certain embodiments, approximately 16 mg / day is administered as a single dose (i.e., once daily), and approximately 8 mg / day is administered as a single dose (i.e., once daily). In certain embodiments, approximately 16 mg / day is administered as two doses of approximately 8 mg each (i.e., approximately 8 mg twice daily), and approximately 8 mg / day is administered as two doses of approximately 4 mg each (i.e., approximately 4 mg twice daily).

[0050] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 24 mg / day, and during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 8 mg / day. In certain embodiments, about 24 mg / day is administered as a single dose (i.e., once daily), and about 8 mg / day is administered as a single dose (i.e., once daily). In certain embodiments, about 24 mg / day is administered as two doses of about 12 mg each (i.e., about 12 mg twice daily), and about 8 mg / day is administered as two doses of about 4 mg each (i.e., about 4 mg twice daily).

[0051] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered orally.

[0052] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical formulation, which is a tablet.

[0053] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered once daily (QD) during the first period. In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered twice daily (BD) during the first period.

[0054] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered once daily (QD) during the second period. In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered twice daily (BID) during the second period.

[0055] In certain embodiments, the first period is approximately 8 to 24 weeks. In certain embodiments, the first period is approximately 8 weeks. In certain embodiments, the first period is approximately 10 weeks. In certain embodiments, the first period is approximately 12 weeks. In certain embodiments, the first period is approximately 16 weeks. In certain embodiments, the first period is approximately 20 weeks. In certain embodiments, the first period is approximately 24 weeks.

[0056] In certain embodiments, the second period is at least 8 weeks. In certain embodiments, the second period is at least 12 weeks. In certain embodiments, the second period is at least 24 weeks.

[0057] In certain embodiments, in compound (I), each position explicitly designated as deuterium has at least 97% deuterium incorporation.

[0058] In certain embodiments, the daily dose administered during the second period is approximately 50% of the daily dose administered during the first period. In certain embodiments, the daily dose administered during the second period is approximately 66.7% of the daily dose administered during the first period. In certain embodiments, the daily dose administered during the second period is approximately 75% of the daily dose administered during the first period.

[0059] A reference to a specified amount of compound (I) or its pharmaceutically acceptable salt includes both a specified amount of compound (I) as a free base and an amount of a pharmaceutically acceptable salt of compound (I) (e.g., phosphate), which is equivalent to a specified amount of compound (I) as a free base (for example, 10.5 mg of compound (I) phosphate is equivalent to 8 mg of compound (I) free base).

[0060] In a particular embodiment, the amount of compound (I) or a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as phosphate) administered in a method for treating alopecia disorders (for example, in a first or second period) is about 4 mg / day (e.g., 4 mg / day), about 8 mg / day (e.g., 8 mg / day), about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day).

[0061] In a particular embodiment, the amount of compound (I) or a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as phosphate) administered in a method for treating alopecia disorders (for example, in a first or second period) is about 8 mg / day (e.g., 8 mg / day), about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day).

[0062] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia disorders (for example, in a first or second period) is about 8 mg / day (e.g., 8 mg / day), about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day). In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is about 8 mg / day (e.g., 8 mg / day), about 12 mg / day (e.g., 12 mg / day), about 16 mg / day (e.g., 16 mg / day), or about 24 mg / day (e.g., 24 mg / day).

[0063] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia disorders (for example, in a first or second period) is about 8 mg / day (e.g., 8 mg / day), about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day). In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is about 16 mg / day to about 32 mg / day, for example, about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day).

[0064] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia disorders (for example, in a first or second period) is 10.6 mg / day of compound (I) phosphate, administered, for example, as a once-daily dose of 10.6 mg or a twice-daily dose of 5.3 mg. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 21.1 mg / day of compound (I) phosphate, administered, for example, as a once-daily dose of 21.1 mg or a twice-daily dose of 10.5 mg. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 31.6 mg / day of compound (I) phosphate, administered, for example, as a once-daily dose of 31.6 mg or a twice-daily dose of 15.8 mg. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is 42.2 mg / day of compound (I) phosphate, which is administered, for example, as a once-daily dose of 42.2 mg or a twice-daily dose of 21.1 mg.

[0065] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia disorders (for example, in a first or second period) is about 8 mg (e.g., 8 mg) twice daily. In certain embodiments, compound (I) is administered twice daily as about 10.5 mg (e.g., 10.5 mg) of compound (I) phosphate.

[0066] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia disorders (for example, in a first or second period) is about 8 mg (e.g., 8 mg) as a single dose once daily or in divided doses twice daily. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia disorders (for example, in a first or second period) is about 12 mg (e.g., 12 mg) as a single dose once daily or in divided doses twice daily. In certain embodiments, compound (I) is administered as a phosphate of compound (I) at a dose of about 15.8 mg (e.g., 15.8 mg) once daily or in divided doses twice daily. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia (for example, in a first or second period) is about 16 mg (e.g., 16 mg) as a single dose once daily or twice daily in divided doses. In certain embodiments, compound (I) is administered as a phosphate of compound (I) in a single dose once daily or twice daily in divided doses, at a dose of about 21.1 mg (e.g., 21.1 mg). In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia (for example, in a first or second period) is about 24 mg (e.g., 24 mg) as a single dose once daily or twice daily in divided doses. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a method for treating alopecia (for example, in a first period) is about 32 mg (e.g., 32 mg) as a single dose once daily or twice daily in divided doses.

[0067] In certain embodiments, the hair loss disorder is alopecia areata. In preferred embodiments, the subject is human. In one embodiment, the subject is human aged 6 years or older. In certain embodiments, compound (I), or a pharmaceutically acceptable salt thereof (such as a phosphate), is administered orally in any of the doses described herein. In certain embodiments, compound (I), or a pharmaceutically acceptable salt thereof, is administered orally in a pharmaceutical formulation, which is a tablet, in any of the doses described herein.

[0068] In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt administered during the second period is a daily amount that is approximately 50% of the daily amount administered during the first period. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt administered during the second period is a daily amount that is approximately 66.7 percent of the daily amount administered during the first period. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt administered during the second period is a daily amount that is approximately 75 percent of the daily amount administered during the first period.

[0069] The following table shows exemplary amounts of compound (I) or its pharmaceutically acceptable salt to be administered. [Table 1]

[0070] In another aspect, the present invention provides a method for treating alopecia areata in a human subject that requires it, the method being: a) Over the first period, the following structural formula [ka] Administering an initial dose of the compound, represented by a pharmaceutically acceptable salt thereof, to a human subject, Each position clearly designated as deuterium has at least 95% deuterium incorporation. The length of the first period is sufficient to achieve a reduction in the patient's SALT score. The initial dose is approximately 8 to 32 mg per day, and thereafter, b) administering a maintenance dose of the compound or a pharmaceutically acceptable salt thereof to a human subject over a second period, wherein the maintenance dose is 50% to 75% of the initial dose and is sufficient to maintain hair growth (e.g., a SALT score of 20 or less).

[0071] In certain embodiments, the length of the first period is sufficient to achieve a reduction in the SALT score of at least 10% of patients relative to baseline (e.g., from a pre-treatment SALT score of 100 to a post-treatment SALT score of 90). In further embodiments, the length of the first period is sufficient to achieve a reduction of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, or at least 90% of the patient's SALT score relative to baseline. In certain embodiments, the length of the first period is sufficient to achieve a reduction in the SALT score of at least 50% of patients relative to baseline. In certain embodiments, the length of the first period is sufficient to achieve a reduction in the SALT score of at least 75% of patients relative to baseline. In certain embodiments, the length of the first period is sufficient to achieve a reduction in the SALT score of at least 90% of patients relative to baseline.

[0072] In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 50 or less, 40 or less, 30 or less, 20 or less, 15 or less, 10 or less, 5 or less, 1 or less, or zero at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 20 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 15 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 10 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 5 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of 1 or less at the end of the first period. In a particular embodiment, the length of the first period is sufficient to achieve a SALT score of zero at the end of the first period.

[0073] In certain embodiments, the maintenance dose is approximately 25% of the initial dose. In certain embodiments, the maintenance dose is approximately 33.3% of the initial dose. In certain embodiments, the maintenance dose is approximately 50% of the initial dose. In certain embodiments, the maintenance dose is approximately 66.7% of the initial dose. In certain embodiments, the maintenance dose is approximately 75% of the initial dose.

[0074] In a particular embodiment, the maintenance dose given during the second period is sufficient to achieve a SALT score of 50 or less, 40 or less, 30 or less, 20 or less, 15 or less, 10 or less, 5 or less, 1 or less, or zero at the end of the second period. In a particular embodiment, the maintenance dose given during the second period is sufficient to achieve a SALT score of 20 or less at the end of the second period. In a particular embodiment, the maintenance dose given during the second period is sufficient to achieve a SALT score of 15 or less at the end of the second period. In a particular embodiment, the maintenance dose given during the second period is sufficient to achieve a SALT score of 10 or less at the end of the second period. In a particular embodiment, the maintenance dose given during the second period is sufficient to achieve a SALT score of 5 or less at the end of the second period. In certain embodiments, the maintenance dose is sufficient to maintain the SALT score achieved in the first period (for example, in certain embodiments, the maintenance dose given in the second period is sufficient to achieve an increase of <10 or <5 points in the target SALT score at the end of the second period compared to the target SALT score at the end of the first period; in certain embodiments, the maintenance dose given in the second period is sufficient to achieve an increase of <30 points in the target SALT score at the end of the second period compared to the target SALT score at the end of the first period; in certain embodiments, the maintenance dose given in the second period is sufficient to maintain the SALT score achieved in the first period The maintenance dose is sufficient to achieve an increase of <5 points and <30 points in the target SALT score at the end of the second period compared to the target SALT score at the end of the first period. In certain embodiments, the maintenance dose is sufficient to achieve an increase of <4 points, <3 points, <2 points, or <1 point in the target SALT score at the end of the second period compared to the target SALT score at the end of the first period. In certain embodiments, the maintenance dose is sufficient to achieve an increase of <20%, <15%, <10%, or <5% in the target SALT score at the end of the second period compared to the target SALT score at the end of the first period.

[0075] In another aspect, the present invention provides a method for treating alopecia disorders in human subjects, the method comprising a compound represented by the following structural formula: [ka] The treatment involves administering the compound or a pharmaceutically acceptable salt thereof to the target, where each position specified in detail as deuterium has at least 95% deuterium incorporation, the compound or a pharmaceutically acceptable salt thereof is first administered during an induction period to initiate initial hair growth, and then administered in a second period to further treat the hair disorder, the induction period being at least 8 weeks and no more than 24 weeks, the amount of the compound or a pharmaceutically acceptable salt thereof administered during the induction period being in the range of 16 mg / day to 32 mg / day, and after the induction period, the amount of the compound or a pharmaceutically acceptable salt thereof is reduced by 50 to 75% (e.g., 50, 66.7, or 75%) in the second period.

[0076] In the above embodiment,

[0077] In certain embodiments, the length of the first period is at least 8 to 24 weeks. In certain embodiments, the first period is about 12 weeks. In certain embodiments, the first period is about 16 weeks. In certain embodiments, the first period is about 20 weeks. In certain embodiments, the first period is about 24 weeks.

[0078] In certain embodiments, the second period is at least 12 weeks long. In certain embodiments, the second period is at least 24 weeks long.

[0079] Exemplary doses for the first and second periods are described above.

[0080] In certain embodiments, the reduction in the patient's baseline SALT score during the first period is approximately 10% to approximately 50%. In certain embodiments, the reduction in the baseline SALT score is approximately 20% to approximately 50%. In certain embodiments, the reduction in the patient's baseline SALT score during the first period is approximately 50%. In certain embodiments, the reduction in the baseline SALT score is approximately 30% to approximately 50%. In certain embodiments, the reduction in the patient's baseline SALT score over the length of the first period is at least 50%. In certain embodiments, the reduction in the baseline SALT score is approximately 50% to approximately 99%. In certain embodiments, the reduction in the baseline SALT score is approximately 50% to approximately 90%. In certain embodiments, the reduction in the baseline SALT score is approximately 50% to approximately 75%. In certain embodiments, the reduction in the baseline SALT score is approximately 75% to approximately 90%.

[0081] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of about 12 mg / day, about 16 mg / day, about 24 mg / day, or about 32 mg / day.

[0082] In certain embodiments, during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 6 mg / day, approximately 8 mg / day, approximately 12 mg / day, or approximately 16 mg / day.

[0083] In certain embodiments during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 24 mg / day, and in the second period, the compound or a pharmaceutically acceptable salt thereof is administered at approximately 16 mg / day. In certain embodiments, approximately 24 mg / day is administered once daily, and approximately 16 mg / day is administered once daily. In certain embodiments, approximately 24 mg / day is administered twice daily as approximately 12 mg (divided dose), and approximately 16 mg / day is administered twice daily as approximately 8 mg (divided dose).

[0084] In certain embodiments, during the first period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of approximately 16 mg / day, and during the second period, the compound or a pharmaceutically acceptable salt thereof is administered at a dose of approximately 8 mg / day.

[0085] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered orally.

[0086] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical formulation that is a tablet. In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical formulation that is a capsule.

[0087] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered once daily during a first period.

[0088] In certain embodiments, the compound or a pharmaceutically acceptable salt thereof is administered twice daily during a first period.

[0089] In certain embodiments of compound (I), each position explicitly designated as deuterium has at least 97% deuterium incorporation.

[0090] In the method of the present invention, the length of the first and second periods may vary depending on factors such as the amount of hair growth induced in the first period (determined, for example, by the SALT score measured before and after the first period) and the desired duration of treatment. The first period may be, for example, 8 to 24 weeks, e.g., 8 weeks, 10 weeks, 12 weeks, 14 weeks, 16 weeks, 18 weeks, 20 weeks, 22 weeks, or 24 weeks. The second period may be, for example, 8 weeks, 16 weeks, 24 weeks, 52 weeks, 2 years, 5 years, 10 years, or 20 years.

[0091] In one embodiment, the first period is at least 24 weeks (e.g., 24 weeks), and the second period is at least 24 weeks (e.g., 24 weeks).

[0092] In another embodiment, the first period is at least 24 weeks (e.g., 24 weeks), and the second period is at least 24 weeks (e.g., 24 weeks).

[0093] In another embodiment, the present invention provides a method for inducing hair growth in a subject. The method comprises administering an effective amount of compound (I) or a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as a phosphate) to a mammalian subject, where each position expressly designated as deuterium has at least 95% deuterium incorporation, and the compound or a pharmaceutically acceptable salt thereof is administered (1) in an amount ranging from 8 to 32 mg per day for a first period of 8 to 24 weeks, and then (2) for a second period of at least 8 weeks, during which the compound or a pharmaceutically acceptable salt thereof is administered in a daily amount that is 50 to 75% (e.g., 50%, 66.7%, 75%) of the daily amount administered in the first period, to induce hair growth in the subject.

[0094] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth is about 4 mg / day (e.g., 4 mg / day), about 8 mg / day (e.g., 8 mg / day), about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), about 32 mg / day (e.g., 32 mg / day), or about 48 mg / day (e.g., 48 mg / day).

[0095] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth is about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day).

[0096] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth is about 8 mg / day (e.g., 8 mg / day), about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day). In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth is about 8 mg / day (e.g., 8 mg / day), about 12 mg / day (e.g., 12 mg / day), about 16 mg / day (e.g., 16 mg / day), or about 24 mg / day (e.g., 24 mg / day).

[0097] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth is 10.6 mg / day of compound (I) phosphate, for example, administered as a once-daily dose of 10.6 mg or a twice-daily dose of 5.3 mg. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 21.1 mg / day of compound (I) phosphate, for example, administered as a once-daily dose of 21.1 mg or a twice-daily dose of 10.5 mg. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 31.6 mg / day of compound (I) phosphate, for example, administered as a once-daily dose of 31.6 mg or a twice-daily dose of 15.8 mg. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 42.2 mg / day of compound (I) phosphate, which is administered, for example, as a once-daily dose of 42.2 mg or a twice-daily dose of 21.1 mg.

[0098] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth (during the second period) is about 4 mg (e.g., 4 mg) twice daily. In certain embodiments, compound (I) is administered twice daily as about 5.3 mg (e.g., 5.3 mg) of compound (I) phosphate.

[0099] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth (during the first or second period) is about 8 mg (e.g., 8 mg) twice daily. In certain embodiments, compound (I) is administered twice daily as about 10.5 mg (e.g., 10.5 mg) of compound (I) phosphate.

[0100] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth (during the first or second period) is about 12 mg (e.g., 12 mg) twice daily. In certain embodiments, compound (I) is administered twice daily as about 15.8 mg (e.g., 15.8 mg) of compound (I) phosphate.

[0101] In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof administered in a manner that induces hair growth (e.g., during a first period) is about 16 mg (e.g., 16 mg) twice daily. In certain embodiments, compound (I) is administered twice daily as about 21.1 mg (e.g., 21.1 mg) of compound (I) phosphate.

[0102] In certain embodiments, the subject suffers from a hair loss disorder, and in further embodiments, the hair loss disorder is alopecia areata. In preferred embodiments, the subject is human. In one embodiment, the subject is human aged 6 years or older. Preferably, compound (I), or a pharmaceutically acceptable salt thereof (such as a phosphate), is administered orally in any of the aforementioned doses. Preferably, compound (I), or a pharmaceutically acceptable salt thereof, is administered orally in a pharmaceutical formulation, which is a tablet or capsule, in any of the doses described herein.

[0103] Hair loss disorders include, but are not limited to, androgenetic alopecia, alopecia areata, telogen effluvium, alopecia totalis, and alopecia universalis.

[0104] In any particular embodiment of the methods described herein, the condition is alopecia areata in a subject such as a mammalian (e.g., human) patient requiring it. In a particular embodiment, the alopecia areata is moderate to severe alopecia areata (e.g., hair loss of more than 30% of the scalp, hair loss of more than 40% of the scalp, hair loss of more than 50% of the scalp, or hair loss of more than 75% of the scalp).

[0105] In one embodiment of any particular aspect, the compound is administered orally once daily. In another embodiment of any particular aspect, the compound is administered orally twice daily.

[0106] The effective dose also varies, as is recognized by those skilled in the art, depending on the disease being treated, the severity of the disease, the route of administration, the sex, age and overall health status of the subject, the use of excipients, the use of other drugs and the judgment of the treating physician, and the possibility of co-administration with other therapeutic treatments.

[0107] Administration of compound (I) or a pharmaceutically acceptable salt thereof (such as a phosphate) may be continued for as long as necessary to treat the alopecia disorder, for example, one week, two weeks, one month, two months, three months, four months, six months, one year, two years, five years, ten years, or longer.

[0108] In a specific embodiment, the treatment is continued for a period of at least 8 weeks, or at least 12 weeks, or at least 16 weeks, or at least 20 weeks, or at least 24 weeks, or at least 28 weeks, or at least 32 weeks, or at least 36 weeks, or at least 40 weeks, or at least 44 weeks, or at least 48 weeks, or at least 52 weeks.

[0109] In certain embodiments, compound (I), or a pharmaceutically acceptable salt thereof, is administered in combination with an additional therapeutic agent. Preferably, the additional therapeutic agent is an agent useful for treating alopecia disorders or autoimmune conditions, such as an inhibitor of JAK1, JAK2, or JAK3 and / or STAT1. Such inhibitors include ruxolitinib, tofacitinib, baricitinib, filgotinib, and the like. Other orally administered additional therapeutic agents include, for example, drugs used to treat alopecia areata, including oral corticosteroids.

[0110] For pharmaceutical compositions containing additional therapeutic agents, the effective dose of the additional therapeutic agent is approximately 20% to 100% of the dose typically used in a monotherapy regimen using that agent alone. Preferably, the effective dose is approximately 70% to 100% of the usual monotherapy dose. The usual monotherapy doses of these additional therapeutic agents are well known in the art. See, for example, Wells et al., Pharmacotherapy Handbook, 2nd edition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000); FDA approval labeling information for ruxolitinib and tofacitinib; and clinical trial information for baricitinib and filgotinib; each of these is incorporated herein by reference in whole.

[0111] Some of the additional therapeutic agents described above may act synergistically with the compounds of the present invention. When synergistic effects occur, the effective dose of the additional therapeutic agent and / or compound (I), or a pharmaceutically acceptable salt thereof, can be reduced from that required in monotherapy. This has the advantages of minimizing toxic side effects of either the additional therapeutic agent or compound (I), or a pharmaceutically acceptable salt thereof, synergistic improvements in efficacy, improved ease of administration or use, and / or a reduction in the overall cost of preparing or formulating the compounds.

[0112] In another embodiment, any of the above treatment methods includes a further step of co-administering one or more additional therapeutic agents to a subject in need thereof. The selection of additional therapeutic agents may be made from any additional therapeutic agents known to be useful in treating alopecia areata or other hair loss disorders. The selection of additional therapeutic agents also depends on the specific disease or condition being treated. Examples of additional therapeutic agents that may be employed in the methods of the present invention are those described above for use in combination compositions comprising compound (I), or a pharmaceutically acceptable salt thereof, and the additional therapeutic agents. Additional therapeutic agents include, for example, agents used in the treatment of alopecia areata, including topical minoxidil, injectable corticosteroids, and anthraline cream or ointment.

[0113] As used herein, the term “combined” means that an additional therapeutic agent may be administered together with compound (I) or a pharmaceutically acceptable salt thereof as part of a single dosage form (such as a composition of the present invention comprising the compound of the present invention and the second therapeutic agent described above) or as a separate dosage form. Alternatively, the additional agent may be administered before, consecutively, or after the administration of compound (I) or a pharmaceutically acceptable salt thereof. In such combination therapy, both compound (I), or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are administered by conventional means. Administration to a subject of a composition of the present invention comprising both compound (I), or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent does not preclude separate administration of the same therapeutic agent, any other additional therapeutic agent, or compound (I), or a pharmaceutically acceptable salt thereof, to the subject at another point in the course of treatment.

[0114] The effective doses of these additional therapeutic agents are well known to those skilled in the art, and guidance for administration can be found in the patents and published patent applications referenced herein, as well as in Wells et al., eds., Pharmacotherapy Handbook, 2nd edition, Appleton and Lange, Stamford, Conn. (2000), PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000), and other medical literature. However, determining the optimal effective dose range of the additional therapeutic agents is well within the authority of those skilled in the art.

[0115] In one embodiment, when an additional therapeutic agent is administered to the subject, the effective dose of compound (I) or a pharmaceutically acceptable salt thereof is likely to be less than the effective dose when the additional therapeutic agent is not administered. In another embodiment, the effective dose of the additional therapeutic agent is less than the effective dose when compound (I) or a pharmaceutically acceptable salt thereof is not administered. Thus, undesirable side effects associated with high doses of either drug can be minimized. Other potential advantages, including but not limited to improved dosing regimens and / or reduced drug costs, will be apparent to those skilled in the art.

[0116] In yet another aspect, the present invention provides the use of compound (I) or a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as a phosphate) as a single composition or separate dosage form, alone or in combination with one or more of the additional therapeutic agents described above in the manufacture of a pharmaceutical product, for the treatment or prevention of the diseases, disorders, or symptoms described herein. Another aspect of the present invention is compound (I) or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of the diseases, disorders, or symptoms described herein.

[0117] Another aspect of the present invention is compound (I) or an equivalent amount of its pharmaceutically acceptable salt in the range of about 4 mg to about 50 mg (e.g., about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, or about 50 mg) together with a pharmaceutically acceptable carrier or diluent. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is about 4 mg, 8 mg, 16 mg, 24 mg, 32 mg, or 48 mg. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is 4 mg, 8 mg, 12 mg, or 16 mg. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is 5.3 mg of compound (I) phosphate. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is 10.5 or 10.6 mg of compound (I) phosphate. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 15.8 mg of compound (I) phosphate. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 21.1 mg of compound (I) phosphate. In certain embodiments, the pharmaceutical composition is a tablet or a capsule.

[0118] Another aspect of the present invention is a unit dosage form comprising compound (I) or an equivalent amount of its pharmaceutically acceptable salt in the range of about 4 mg to about 50 mg (e.g., about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, or about 50 mg) together with a pharmaceutically acceptable carrier or diluent. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is about 4 mg, 8 mg, 16 mg, 24 mg, 32 mg, or 48 mg. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is 4 mg, 8 mg, 12 mg, or 16 mg. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is 5.3 mg of compound (I) phosphate. In certain embodiments, the amount of compound (I) or its pharmaceutically acceptable salt is 10.5 or 10.6 mg of compound (I) phosphate. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 15.8 mg of compound (I) phosphate. In certain embodiments, the amount of compound (I) or a pharmaceutically acceptable salt thereof is 21.1 mg of compound (I) phosphate. In certain embodiments, the unit dosage form is a tablet or a capsule.

[0119] In one embodiment, any atom not designated as deuterium is present in compound (I) in its natural isotopic abundance or in a pharmaceutically acceptable salt thereof.

[0120] The synthesis of compound (I), or its pharmaceutically acceptable salts (such as phosphates), can be readily achieved by the methods described in U.S. Patent No. 9,249,149, PCT Patent Publication WO2017 / 192905, or PCT Patent Publication WO2020 / 163653, the teachings thereof, with appropriate modifications, are incorporated herein by reference. For example, U.S. Patent No. 9,249,149 describes the use of D9-intermediate 15 and intermediate A for the production of D9-ruxolitinib in the method described in U.S. Patent No. 9,249,149, [ka] Compound (I) is provided. Furthermore, intermediate B is [ka] To prepare compound (I), intermediate 14 of U.S. Patent No. 9,249,149 can be used instead, and the removal of the amino protecting group can be achieved using basic cleavage (e.g., using sodium hydroxide). Compound (I) (free base) can be converted to its phosphate using phosphoric acid. An additional method for preparing ruxolitinib (i.e., non-deuterated compound (I)) is disclosed in U.S. Patent No. 9,000,161 and can be used to prepare compound (I) using a suitable deuterating reagent.

[0121] These methods can be used to synthesize the compounds detailed herein, or to introduce isotopic atoms into their chemical structures, by invoking standard synthesis protocols known in the art, using the corresponding deuterides and optionally other isotope-containing reagents and / or intermediates.

[0122] The present invention also provides a pharmaceutical composition comprising an effective amount of compound (I), or a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as a phosphate), and a pharmaceutically acceptable carrier. The carrier is "acceptable" in the sense that it is compatible with the other components of the formulation, and in the case of a pharmaceutically acceptable carrier, in the sense that it is not harmful to its recipient in the amount used in the drug. In certain embodiments, the pharmaceutical composition is provided as a unit dosage form.

[0123] The present invention relates to a pharmaceutically acceptable carrier or diluent and 4 to 50 mg of a compound represented by the following structural formula: [ka] The present invention provides a pharmaceutical composition comprising either a pharmaceutically acceptable salt thereof (i.e., an equivalent amount of a pharmaceutically acceptable salt such as a phosphate), for example, the amount of compound (I) is 4 mg, 8 mg, 12 mg, 16 mg, or 24 mg. Compound (I)

[0124] Pharmaceutically acceptable carriers, adjuvants, and vehicles that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, e.g., human serum albumin, buffers, e.g., phosphoric acid, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxypropylene-block polymer, polyethylene glycol, and wool fat.

[0125] Where necessary, the solubility and bioavailability of the compounds of the present invention in pharmaceutical compositions can be enhanced by methods well known in the art. One method involves the use of lipid excipients in formulations. See "Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs (Drugs and the Pharmaceutical Sciences)" by David J. Hauss, ed., Informa Healthcare, 2007; and "Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples" by Kishor M. Wasan, ed., Wiley-Interscience, 2006.

[0126] Another known method for enhancing bioavailability is the use of amorphous forms of the compounds of the present invention, optionally formulated with poloxamers such as LUTROL® and PLURONIC® (BASF Corporation), or block copolymers of ethylene oxide and propylene oxide. See U.S. Patent No. 7,014,866 and U.S. Patent Publications 20060094744 and 20060079502.

[0127] The pharmaceutical compositions of the present invention include those suitable for oral administration. Other formulations may be conveniently presented in unit dosage forms such as tablets, sustained-release capsules, granules, and liposomes, and may be prepared by any method well known in the pharmaceutical art. See, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, Baltimore, MD (20th edition, 2000).

[0128] These preparative methods involve the step of associating molecules with administered components, such as carriers that constitute one or more minor components. Generally, compositions are prepared by homogeneously and closely associating the active ingredient with a liquid carrier, liposomes, or finely divided solid carrier, or both, and then, if necessary, forming a product.

[0129] In certain embodiments, the compound is administered orally. Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets, or tablets, each containing a predetermined amount of the active ingredient, powder or granules, solution or suspension in an aqueous or non-aqueous liquid, oil-in-water liquid emulsion, or water-in-oil liquid emulsion, either filled into liposomes or as a bolus. Soft gelatin capsules may be useful for containing such suspensions, which can advantageously increase the absorption rate of the compound. In certain embodiments, the compound is administered orally as a tablet. In another particular embodiment, the compound is administered orally in a capsule.

[0130] For oral tablets, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When an aqueous suspension is administered orally, the active ingredient is combined with an emulsifier and a suspending agent. If desired, certain sweeteners and / or flavoring agents and / or coloring agents may be added. In another embodiment, the composition is in the form of a tablet. In a particular embodiment, exemplary formulations for tablets are disclosed in U.S. Patent No. 8,754,224, the teachings of which are incorporated herein by reference.

[0131] In certain embodiments, the tablet formulation contains approximately 4 mg to approximately 50 mg of compound (I) or a pharmaceutically acceptable salt thereof (such as a phosphate), and equivalent amounts of colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and the inactive component povidone. Compression following a wet granulation process provides tablets containing compound (I) or a pharmaceutically acceptable salt thereof. For example, to prepare a 200 mg tablet containing an equivalent 16 mg of compound (I), 10.6 wt% compound (I) phosphate and 64.44 wt% Avicel PH-101 microcrystalline cellulose are mixed in a high-shear granulator; 8.5% w / w Kollidon 30 solution (containing Kollidon 30, polyvinylpyrrolidone (povidone)) is added; and 5 wt% (based on the total weight of the formulation) is added while mixing to form granules. The granules are tray-dried in an oven at 60±10℃ and ground using a Quadro Comil U5 mill. The granules held on the Comil screen are passed through a #20 mesh sieve using a stainless steel spatula. The resulting ground granules are mixed with Avicel PH-200 microcrystalline cellulose (18.5 wt%), Aerosil 200 colloidal silicon dioxide (0.5 wt%), and Hyqual magnesium stearate (1 wt%) in a Turbula mixer to form the final mixture. The final mixture is compressed into 200 mg tablets using a Riva Piccola rotary press equipped with a 0.451” × 0.229” D-type modified capsule shaping tool. Each tablet contains 21.1 mg of compound(I) (equivalent to 16 mg of compound(I) free base).

[0132] In certain embodiments, the tablets contain about 10.5 mg or about 10.6 mg of compound (I) phosphate (equivalent to 8 mg of compound (I) free base).

[0133] In certain embodiments, the tablets contain the following ingredients: [Table 2]

[0134] In another specific embodiment, the tablet contains the following ingredients: [Table 3]

[0135] In an alternative specific embodiment, the tablet contains the following ingredients: [Table 4]

[0136] In yet another specific embodiment, the tablet contains the following ingredients: [Table 5]

[0137] In another embodiment, the pharmaceutical composition of the present invention further comprises an additional therapeutic agent. The additional therapeutic agent may be selected from any compound or therapeutic agent known to have or exhibiting advantageous properties when administered together with a compound having the same mechanism of action as ruxolitinib.

[0138] Preferably, additional therapeutic agents are drugs useful for treating alopecia disorders or autoimmune conditions, including inhibitors of JAK1, JAK2, or JAK3 and / or STAT1. Such inhibitors include ruxolitinib, tofacitinib, baricitinib, filgotinib, and others. Other additional therapeutic agents include oral corticosteroids.

[0139] In another embodiment, the present invention provides one or more separate dosage forms of compound (I) or a pharmaceutically acceptable salt thereof, and the additional therapeutic agents described above, wherein compound (I) or a pharmaceutically acceptable salt thereof, and the additional therapeutic agents are related to each other. As used herein, the term “related to each other” means that the separate dosage forms are packaged together or sold together, and are attached to each other in such a way that it is readily apparent that they are intended to be administered (sequentially or simultaneously, within less than 24 hours of each other).

[0140] In the pharmaceutical composition of the present invention, compound (I) or a pharmaceutically acceptable salt thereof is present in an effective amount. As used herein, the term “effective amount” means an amount sufficient to treat a targeted disorder when administered in an appropriate dosing regimen.

[0141] The interrelationship between animal and human doses (based on milligrams per square meter of body surface) is described in Freireich et al., Cancer Chemother. Rep, 1966, 50:219. Body surface area can be roughly determined from the subject's height and weight. See, for example, Scientific Tables, Geigy Pharmaceuticals, Ardsley, NY, 1970, 537.

[0142] In one embodiment, an effective amount of compound (I) (either as a free base or as an equivalent amount of a pharmaceutically acceptable salt such as a phosphate) may be in the range of about 8 mg to 32 mg per day (e.g., 8 mg to 32 mg per day), for example, about 10 mg / day (e.g., 10 mg / day), for example, about 20 mg / day (e.g., 20 mg / day), or about 30 mg / day (e.g., 30 mg / day). In a particular embodiment, the amount is about 8 mg / day (e.g., 8 mg / day), about 12 mg / day (e.g., 12 mg / day), about 16 mg / day (e.g., 16 mg / day), about 24 mg / day (e.g., 24 mg / day), or about 32 mg / day (e.g., 32 mg / day). In certain embodiments, approximately 8 mg / day (e.g., 8 mg / day), approximately 16 mg / day (e.g., 16 mg / day), approximately 24 mg / day (e.g., 24 mg / day), or approximately 32 mg / day (e.g., 32 mg / day) is administered once daily. In certain examples, the 16 mg / day dose is administered as two 8 mg tablets of compound (I) (as a free base or as an equivalent amount of a pharmaceutically acceptable salt such as phosphate) together (i.e., as a single dose). In other specific examples, the 16 mg / day dose is administered as one 16 mg tablet of compound (I) (as a free base or as an equivalent amount of a pharmaceutically acceptable salt such as phosphate). In another embodiment, doses of 8 mg / day, 16 mg / day, 24 mg / day, or 32 mg / day are administered in divided doses twice daily (for example, a 16 mg / day dose is administered twice daily as 8 mg / day, or a 24 mg / day dose is administered twice daily as 12 mg / day). In another embodiment, doses of 8 mg / day, 16 mg / day, 24 mg / day, or 32 mg / day are administered in divided doses twice daily (for example, a 32 mg / day dose is administered as 16 mg of compound(I) (either as a free base or as an equivalent of a pharmaceutically acceptable salt such as a phosphate), i.e., in separate doses twice daily). In a particular embodiment, a 16 mg / day dose is administered as 8 mg of compound(I) (either as a free base or as an equivalent of a pharmaceutically acceptable salt such as a phosphate), i.e., in separate doses.References to compound (I) or a pharmaceutically acceptable amount of its salt include a pharmaceutically acceptable amount of compound (I) (such as phosphate), which is equivalent to a given amount of compound (I) as free base (for example, 10.5 mg of compound (I) phosphate is equivalent to 8 mg of compound (I) free base).

[0143] In certain embodiments, an effective amount of compound (I), or a pharmaceutically acceptable salt thereof, is about 4 mg (e.g., 4 mg) twice daily. In certain embodiments, an effective amount of compound (I) is administered twice daily as about 5.3 mg (e.g., 5.3 mg) of compound (I) phosphate. In certain embodiments, an effective amount of compound (I), or a pharmaceutically acceptable salt thereof, is about 8 mg (e.g., 8 mg) twice daily. In certain embodiments, compound (I) is administered twice daily as about 10.5 mg (e.g., 10.5 mg) of compound (I) phosphate.

[0144] In certain embodiments, an effective amount of compound (I) or a pharmaceutically acceptable salt thereof is about 12 mg (e.g., 12 mg) twice daily. In certain embodiments, an effective amount of compound (I) is about 15.8 mg (e.g., 15.8 mg) of compound (I) phosphate twice daily. In certain embodiments, an effective amount of compound (I) or a pharmaceutically acceptable salt thereof is about 16 mg (e.g., 16 mg) twice daily. In certain embodiments, an effective amount of compound (I) is about 21.1 mg (e.g., 21.1 mg) of compound (I) phosphate twice daily. [Examples]

[0145] Example 1 - Human Study - Phase 2a A Phase 2a trial was conducted to evaluate the safety and efficacy of compound (I) (CTP-543) in patients with alopecia, with a primary efficacy analysis performed at 24 weeks. The Phase 2a trial was a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of compound (I) in adult patients with moderate to severe alopecia areata. Patients were sequentially randomized to receive one of three doses of compound (I) as phosphate (e.g., 10.5 mg of compound (I) phosphate is equivalent to 8 mg of compound (I) free base). Doses of compound (I) were 4, 8 (i.e., approximately 10.5 mg of compound (I) phosphate), and 12 mg twice daily, with a placebo group also receiving treatment. The primary outcome measure was the severity of alopecia tool (SALT) after 24 weeks of administration.

[0146] Interim top-line analyses for the 4 mg, 8 mg, and 12 mg cohorts are described below. The primary endpoint of this study was a 50% relative reduction in SALT between week 24 and baseline.

[0147] The demographic characteristics of participants enrolled in the study and administered 4, 8, or 12 mg (twice daily) or placebo are shown in Table 1 below. [Table 6] The baseline characteristics of the target are shown in Table 2 below. [Table 7]

[0148] The most common adverse events experienced by patients (10% or more) under treatment are shown in Table 3 below. [Table 8]

[0149] No serious adverse events were reported. In a preliminary analysis of the placebo, 4 mg, and 8 mg groups, only three grade 3 / 4 hematological events were evenly distributed across the placebo, 4 mg, and 8 mg groups.

[0150] In conclusion, the primary efficacy endpoint of the trial was met. 58% of patients treated with 12 mg BID (twice daily) and 47% of patients treated with 8 mg BID (twice daily) showed a ≥50% reduction in overall SALT score compared to 8.6% in placebo (p<0.001). Furthermore, 42% of patients treated with 12 mg BID (twice daily) (p<0.001) and 29% of patients treated with 8 mg BID (twice daily) (p<0.05) showed a ≥75% reduction in overall SALT score compared to 7% in placebo. Furthermore, 36% of patients treated with 12 mg BID (p<0.001) and 16% of patients treated with 8 mg BID (p<0.05) achieved a reduction of 90% or more in overall SALT scores compared to 2% in placebo. 21% of patients treated with 4 mg BID CTP-543 achieved a reduction of 50% or more in overall SALT scores compared to 8.6% in placebo (not statistically significant). The 12 mg and 8 mg BID dose groups differed significantly from the 4 mg BID dose group (p<0.05). Significant changes in SALT scores were observed in the 12 mg and 8 mg cohorts compared to placebo, starting at 12 weeks (p<0.05).

[0151] The treatment was generally well-tolerated, and there were no serious adverse events. The 4 mg BID dose could not be isolated from placebo on any scale. At week 24, the 8 mg and 12 mg BID doses were significantly different from placebo on all SALT scales, which are the conclusions of the study. The 12 mg BID dose was numerically superior to the 8 mg BID dose and generally resulted in faster onset and greater efficacy.

[0152] Example 2 - Open-label long-term administration study In the ongoing open-label long-term administration study, subjects who had previously enrolled in an eligible clinical trial (including the trial described in Example 1) and received either a total daily dose of 16 mg of compound (I) (CTP-543, phosphate), a total daily dose of 24 mg of CTP-543, or placebo, and completed the 24-week treatment period, were eligible to enroll in the open-label long-term administration study (OLE) and continue treatment with CTP-543 phosphate. A total of 152 subjects were enrolled in the OLE. In the OLE, subjects received daily treatment with CTP-543 at doses of 8 mg BID or 12 mg BID (see Figure 8). Dose adjustments were permitted at the discretion of the principal investigator. One subject enrolled in OLE received a daily dose of 24 mg of QD CTP-543 for approximately 9 months (i.e., the 24-week study period of OLE and the first 3 months) and experienced hair growth at that dose (SALT score zero, i.e., complete hair regrowth before dose reduction). Subsequently, the subject's daily dose was reduced to 8 mg of BID CTP-543 phosphate. In OLE, approximately 7 months after receiving the lower dose of 8 mg of BID CTP-543 daily, the subject substantially maintained hair regrowth with a SALT score of 7.92.

[0153] Example 3 - Phase 2 persistence test The Phase 2 clinical trial will be conducted as a two-part, double-blind, randomized, multicenter study to evaluate hair regrowth after treatment with compound (I) (CTP-543) and the subsequent persistence of that regrowth after dose reduction or discontinuation of the drug in adult patients with moderate to severe alopecia areata. Patients will be 18–65 years of age and have experienced an episode of alopecia-related hair loss of at least 6 months, 10 years of age or younger. Patients with alopecia areata, or those not receiving other treatments that may affect hair regrowth or immune response, must have at least 50% hair loss as measured by the Severity of Alopecia Tool (SALT) at screening and baseline. Up to approximately 75% of patients with complete or near-complete (SALT ≥ 95) hair loss will be enrolled.

[0154] The exam is divided into two parts:

[0155] Part A: Phase 1 (Therapy Phase) and Phase 2 (Dose Adjustment Phase)

[0156] Part B: Retreatment Phase

[0157] Part A: Season 1 Part A, Phase 1, is a double-blind treatment period in which approximately 200 or 300 patients will be randomized to receive one of two doses of compound (I) (CTP-543) phosphate (e.g., 10.5 mg of compound (I) phosphate is equivalent to 8 mg of compound (I) free base) for 24 weeks. The doses are either 8 mg of compound (I) twice daily (BID) (i.e., approximately 10.5 mg of compound (I) phosphate) or 12 mg of compound (I) twice daily (i.e., approximately 15.8 mg of compound (I) phosphate). Randomization will be stratified by hair loss into one of two categories: 1) partial hair loss (SALT ≥ 50 and < 95); 2) complete or near-complete hair loss (SALT ≥ 95). Patients will receive their first dose of the investigational drug at the clinic on day 1 and will be instructed to administer the drug daily, approximately every 12 hours, throughout Phase 1. Other baseline assessments for Part A, Phase 1 include Patient and Clinician Global Impression of Disease Severity (CGI-S and PGI-S), as well as Patient Reported Outcome for Satisfaction (SPRO) and Hair Quality (QPRO). Blood samples for pharmacokinetic assessment will be taken regularly. Scalp photographs will also be taken to provide a visual record during SALT assessments and will be performed at additional elective visits throughout the study. The primary efficacy analysis to determine responders for each dose group will be performed when all patients have completed week 24 of Part A, Phase 1. In some embodiments, at Part A, End of Treatment (EOT), patients with a SALT score change of <50% from baseline are defined as non-responders who may have the opportunity to continue treatment in an open-label extension trial or complete treatment at 24 weeks and return for 4 weeks for post-treatment safety follow-up.

[0158] In some embodiments, patients from each dose group who have a SALT score change of 50% or more from baseline at week 24 are defined as responders and enter Part A, Phase 2.

[0159] In some embodiments, at the end of treatment (EOT) of Part A, Phase 1, treatment success (responders) are defined as patients from each dose group whose SALT score is 20 or less at week 24. These responders enter Part A, Phase 2 of the study. Patients with a SALT score >20 are defined as non-responders and have the opportunity to continue treatment in an open-label extension study or complete treatment at week 24 and return for 4 weeks for post-treatment safety follow-up.

[0160] Part A, Phase 1 (treatment phase), lasts for 24 weeks. Treatment response using SALT for efficacy will be evaluated at weeks 4, 8, 12, 16, 20, and 24.

[0161] Part A: Season 2 In Part A, Phase 2, patients are re-randomized to receive either a lower dose of Compound (I) (4 mg BID for patients previously receiving 8 mg BID, and 8 mg BID for patients previously receiving 12 mg BID) or placebo. Patients in Part A, Phase 2 continue on their assigned dose for up to 24 weeks, or until they meet the criteria for Loss of Hair Regrowth Maintenance (LOM). LOM is defined as a SALT score greater than 20. Any patient who meets the LOM criterion at any evaluation point during Part A, Phase 2 enters Part B of the study and returns to their original Compound (I) treatment from Part A, Phase 1 (8 mg BID or 12 mg BID). Patients who do not meet the LOM criterion at the end of 24 weeks (i.e., SALT score ≤ 20) can continue treatment in an open-label extension study at their original Part A, Phase 1 dose, or complete treatment at 24 weeks and return for 4 weeks for post-treatment safety follow-up. The study design is shown in Figure 7.

[0162] Part A, Phase 2 (dose adjustment) will continue for a maximum of 24 weeks, or until the patient meets the LOM criteria. The treatment response using SALT for efficacy will be evaluated monthly until the LOM criteria are met or the 24-week period is completed.

[0163] Part B: Any patient in Part A, Phase 2 who meets the LOM criterion (SALT > 20) will enter Part B of the study and return to their initial 8 mg BID or 12 mg BID from Part A, Phase 1. In some embodiments, patients will continue their assigned dose for 24 weeks, regardless of whether they meet the Restoration of Regrowth (ROR) criterion. In some embodiments, patients will continue their assigned dose for 24 weeks or until they meet the Restoration of Regrowth (ROR) criterion. In some embodiments, ROR is defined as the patient achieving a SALT score ≤ original EOT SALT score at the end of Phase 1 of Part A. In some embodiments, ROR is defined as the patient achieving a SALT score ≤ 20. In some embodiments, any patient who meets the ROR criterion at any evaluation point in Part B will terminate the study and be eligible to enroll in an open-label extension study. Evaluation of the treatment response with SALT for efficacy will be performed monthly until the Restoration of Regrowth (ROR) criterion is met or the 24-week period is completed. Patients who do not meet the ROR criteria may have the opportunity to continue treatment in an open-label extension trial, or they may complete treatment at 24 weeks and return for 4 weeks for post-treatment safety follow-up.

[0164] Without further description, it is assumed that those skilled in the art can use the foregoing description and exemplary examples to prepare and utilize the compounds of the present invention and carry out the claimed methods. It should be understood that the foregoing discussion and examples merely provide a detailed description of certain preferred embodiments. It will be apparent to those skilled in the art that various modifications and equivalents can be prepared without departing from the spirit and scope of the invention.

Claims

1. 1. A pharmaceutical composition comprising compound (I) represented by the following structural formula, or a pharma- ceutical acceptable salt thereof, for use in a method for treating hair loss disorders in a human subject: 【Chemistry 1】 wherein each position specifically designated as deuterium has at least 95% deuterium incorporation; said method comprising orally administering to a subject said compound, or a pharma- ceutically acceptable salt thereof, (1) in an amount ranging from about 16 mg to about 32 mg per day for a first period of 8 to 24 weeks, followed by (2) a second period of at least 8 weeks, said compound, or a pharma- ceutically acceptable salt thereof, in an amount ranging from 50 to 75% of the daily amount administered during said first period, thereby treating said hair loss disorder.

2. 2. The pharmaceutical composition of claim 1, wherein the hair loss disorder is alopecia areata.

3. The pharmaceutical composition of any one of claims 1 to 2, wherein during the first period, the compound or a pharma- ceutically acceptable salt thereof is administered at about 16 mg / day, about 24 mg / day, or about 32 mg / day.

4. 4. The pharmaceutical composition of any one of claims 1 to 3, wherein during the second period, the compound or a pharma- ceutically acceptable salt thereof is administered orally at about 8 mg / day, about 12 mg / day, or about 16 mg / day.

5. 5. The pharmaceutical composition of claim 1, wherein during the first period, the compound or a pharma- ceutically acceptable salt thereof is administered orally at about 24 mg / day, and during the second period, the compound or a pharma- ceutically acceptable salt thereof is administered orally at about 16 mg / day.

6. 6. The pharmaceutical composition of claim 5, wherein said about 24 mg / day of said compound or salt thereof is administered orally once daily and said about 16 mg / day is administered orally once daily.

7. 6. The pharmaceutical composition of claim 5, wherein the about 24 mg / day of the compound or salt thereof is administered orally as about 12 mg twice a day, and the about 16 mg / day of the compound or salt thereof is administered orally as about 8 mg twice a day.

8. 5. The pharmaceutical composition of claim 1, wherein during the first period, the compound or a pharma- ceutically acceptable salt thereof is administered orally at about 16 mg / day, and during the second period, the compound or a pharma- ceutically acceptable salt thereof is administered orally at about 8 mg / day.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the compound or a pharma- ceutically acceptable salt thereof is administered orally in a pharmaceutical formulation that is a tablet.

10. The pharmaceutical composition of any one of claims 1-6 or 8-9, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily during the first period of time.

11. 10. The pharmaceutical composition of any one of claims 1-5 or 7-9, wherein said compound or a pharma- ceutically acceptable salt thereof is administered orally twice daily during said first period of time.

12. The pharmaceutical composition of any one of claims 1 to 11, wherein the first period of time is about 8 to 12 weeks.

13. The pharmaceutical composition of any one of claims 1 to 11, wherein the first period of time is about 24 weeks.

14. The pharmaceutical composition of any one of claims 1 to 13, wherein the second period of time is at least 12 weeks.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the second period of time is at least 24 weeks.

16. 16. The pharmaceutical composition according to any one of claims 1 to 15, wherein in compound (I), each position specifically designated as deuterium has at least 97% deuterium incorporation.

17. 17. The pharmaceutical composition of any one of claims 1-16, wherein the subject experiences a 50% or greater decrease in SALT score at the end of the first period compared to the subject's baseline SALT score prior to treatment.

18. The pharmaceutical composition of any one of claims 1 to 17, wherein the subject's SALT score is 20 or less at the end of the second period.

19. The pharmaceutical composition of any one of claims 1 to 16, wherein the subject's SALT score is 20 or less at the end of the first period.